In Episode 1, Part 3, Jon Hamrick, Rena Goins and Bob Cochran explain why specialty networks should start small and how to balance access, data and support.
In Episode 1, Part 1, Jon Hamrick, Rena Goins and Bob Cochran discuss how 340B, the IRA, specialty therapies and launch planning have reshaped the role of commercial trade.
Thani Jambulingam, Ph.D., says MFN pricing, Section 232 tariffs and PBM reform will converge to shape how pharma launches and commercializes new drugs.
CVS Health’s proposed separation of its retail pharmacy business from insurance and pharmacy benefit management raises a fundamental question: Will changing ownership improve pharmaceutical distribution, competition and patient access, or simply redistribute market power?
Jon Hamrick, partner at Curatio Advisors, discusses how product attributes, company size and stakeholder alignment shape pharma commercialization strategy.
At LogiPharma USA 2026, Mark Talens explains how end-to-end visibility lets pharma see its value chain across functions, and where supply chain monitoring is headed next.